News | April 07, 2022
Indian pharma growth likely to moderate in FY23: ICRA
Headwinds related to pricing pressures and rising raw material costs will result in some contraction in margins in Q4 FY22 and FY23
Headwinds related to pricing pressures and rising raw material costs will result in some contraction in margins in Q4 FY22 and FY23
Ind-Ra maintains a neutral outlook for healthcare in FY23
The Gujarat Biotechnology policy released last month has made radical changes to position the state as a biotechnology hub. It already has a thriving ecosystem of pharma companies and varied suppliers
The company plans to establish a state-of-the-art greenfield pharma facility with a total of 4-6 manufacturing units in different therapeutics categories to cater to domestic and export markets
Large players are adequately capitalised to make bigger investments to adjust for the ongoing fundamental shift in market opportunities
Fitch estimates JPL's EBITDA to drop significantly in FY23 due to lower volume and narrowing of the margin to 11% (FY22 estimate: 14%).
The capex during the last nine months has been around Rs 110 crores which is all funded through internal accruals
Key takeaways of recent quarter & conference call highlights
Aster DM Healthcare has reported consolidated financial results for the period ended December 31, 2021
Key takeaways of recent quarter & conference call highlights
Subscribe To Our Newsletter & Stay Updated
